How I manage Evans Syndrome and AIHA cases in children

Area of Science:

• Pediatric Hematology
• Immunology
• Clinical Therapeutics

Background:

• Evans Syndrome (ES) management in children presents therapeutic challenges due to scarce evidence-based treatment guidelines.
• Corticosteroids are the primary treatment, achieving remission in approximately 80% of pediatric patients.
• Refractory, relapsing, or steroid-dependent cases require alternative strategies, excluding autoimmune lymphoproliferative syndrome (aLPS).

Purpose of the Study:

• To provide an overview of the pathogenic background of Evans Syndrome.
• To suggest a clinical approach for diagnosing and treating pediatric Evans Syndrome.
• To focus on strategies for managing relapsing or treatment-resistant Evans Syndrome.

Main Methods:

• Literature review of current treatment protocols for pediatric Evans Syndrome.
• Analysis of immunological mechanisms contributing to cytopenias in Evans Syndrome.
• Synthesis of diagnostic and therapeutic approaches for Evans Syndrome management.

Main Results:

• Steroids are effective in about 80% of pediatric Evans Syndrome cases.
• Rituximab is a viable second-line therapy for steroid-resistant or dependent Evans Syndrome.
• Alternative treatments like mycophenolate mofetil and sirolimus are options for specific cases, such as those with underlying aLPS.

Conclusions:

• Enhanced understanding of immunological drivers can facilitate targeted therapies for Evans Syndrome.
• Newer immunosuppressive agents may reduce reliance on long-term steroids or aggressive treatments like splenectomy or stem cell transplantation.
• A structured clinical approach is crucial for optimizing Evans Syndrome management in children, particularly for refractory cases.